Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) as Add-on to Ezetimibe Therapy in Patients With Elevated LDL-C (CLEAR Tranquility)

Inclusion Criteria: * Fasting LDL-cholesterol greater than or equal to 100 mg/dL at screening * Men and nonpregnant, nonlactating women * Use of stable lipid-modifying therapy for at least 4 weeks prior to screening that includes ezetimibe 10mg daily Exclusion Criteria: * Fasting blood triglycerides greater than or equal to 500 mg/dL * Body Mass Index (BMI) greater than or equal to 50 kg/m2 * Recent history of clinically significant cardiovascular disease * Use of statin therapy where doses are greater than those defined as "low-dose" within 4 weeks prior to screening; where "low-dose" is defined as an average daily dose of rosuvastatin 5 mg, atorvastatin 10 mg, simvastatin 10 mg, lovastatin 20 mg, pravastatin 40 mg, fluvastatin 40 mg, or pitavastatin 2 mg.